A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer
Panagiotis A. Konstantinopoulos(Harvard University), Ronnie Shapira‐Frommer(Sheba Medical Center), Samuel McNeely(Eli Lilly (United States)), Ignace Vergote(KU Leuven), Rowan Miller(University College Hospital), Bo Gao(Blacktown & Mount Druitt Hospital), Jung‐Yun Lee(Yonsei University), Jungmin Lee(National Cancer Institute), Nicoletta Colombo(University of Milan), Suzanne R.L. Young(Eli Lilly (United States)), Xuejing Aimee Wang(Eli Lilly (United States)), Aimee Bence Lin(Eli Lilly (United States)), Kelly M. Credille(Eli Lilly (United States))
Cited by 66
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k